Lilly’s 340B Contract Pharmacy Ban Has Crept Into In-House Pharmacies

Note from the Publisher and CEO Ted Slafsky: I want to acknowledge this date, Sept. 11, and its solemn importance to our country. We honor those who were lost 19 years ago today and continue to cherish the great work of our first responders.

We’re pleased to include in today’s issue sponsored content from 340B Report sponsor SPARx, a division of Comprehensive Pharmacy Services. I encourage you check out the video below featuring SPARx Senior Vice President Michael Heinrichs, describing recent activity surrounding specialty medications.


Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


*Sign up for news summaries and alerts from 340B Report

Site Footer